New alliance will target major risk factor for Alzheimer's

Share this article:

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.

Share this article:
close

Next Article in Products

More in Products

Stents safe for stroke prevention, study says

Placing a stent to keep a neck artery open is as effective as invasive neck surgery for long-term prevention of strokes, according to results from a European trial.

Honeywell Introduces remote patient monitor

Honeywell Introduces remote patient monitor

Honeywell has launched the HomMed Genesis DM™ v4.15, a new version of the remote patient monitor with new peripheral devices.

NKF launches interactive nutrition portal

NKF launches interactive nutrition portal

The National Kidney Foundation has debuted My Food Coach, an interactive nutrition panel meant to allow people to easily manage nutritional requirements.